There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biohaven Ltd. (BHVN – Research Report), PROCEPT BioRobotics (PRCT – Research Report) and Travere Therapeutics (TVTX – Research Report) with bullish sentiments.
Biohaven Ltd. (BHVN)
In a report issued on October 7, Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Ltd.. The company’s shares closed last Wednesday at $51.27.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
Currently, the analyst consensus on Biohaven Ltd. is a Strong Buy with an average price target of $63.45, implying a 18.6% upside from current levels. In a report issued on September 25, Jefferies also initiated coverage with a Buy rating on the stock with a $64.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
PROCEPT BioRobotics (PRCT)
In a report issued on October 7, Mike Kratky from Leerink Partners reiterated a Buy rating on PROCEPT BioRobotics, with a price target of $78.00. The company’s shares closed last Wednesday at $74.14.
According to TipRanks.com, Kratky is a 4-star analyst with an average return of
PROCEPT BioRobotics has an analyst consensus of Strong Buy, with a price target consensus of $80.25, an 8.4% upside from current levels. In a report issued on October 8, TD Cowen also maintained a Buy rating on the stock with a $99.00 price target.
Travere Therapeutics (TVTX)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Travere Therapeutics on October 8 and set a price target of $20.00. The company’s shares closed last Wednesday at $17.59.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of
Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $19.62, representing a 25.4% upside. In a report issued on September 27, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.
Read More on BHVN:
